Literature DB >> 23810735

CD4(+)FoxP3(+) T regulatory cells in drug-susceptible and multidrug-resistant tuberculosis.

Hyo-Jeong Lim1, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyoung Un Park, Choon-Tack Lee, Jae Ho Lee.   

Abstract

Regulatory T cells (Treg) increase in active tuberculosis (TB). However, whether Treg-mediated immune suppression affect the susceptibility to active TB or development of multidrug-resistant (MDR) TB is not yet clear. We compared circulatory Treg frequencies in drug susceptible (DS) and MDR TB before and after anti-TB treatment. Circulatory Treg frequencies were measured in blood samples from 33 DS TB, 7 mycobacterial culture-positive active MDR TB, 16 stable MDR TB who had been culture negative for at least 6 months, and 14 healthy controls before and after treatment. Treg frequency was measured by flow cytometry using cell-surface marker CD4 and intracellular marker FoxP3. Treg frequency was higher in DS TB and active MDR TB patients than in healthy controls (p < 0.05), with no significant difference between the former. Treg frequency was higher in patients with sputum acid-fast bacilli smear-positive TB than in patients with smear-negative TB, but the increase did not correlate with the radiologic extent of TB or presence of a cavity. After successful treatment, Treg decreased to control levels in DS TB and MDR TB patents. The pattern of change, in which Treg frequency increased during active infection and normalized to control levels after successful treatment, was similar in DS and MDR TB patients.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease susceptibility; FoxP3 protein; Multidrug-resistant tuberculosis; Regulatory T-cells

Mesh:

Substances:

Year:  2013        PMID: 23810735     DOI: 10.1016/j.tube.2013.06.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  14 in total

1.  Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.

Authors:  Markus Maeurer; Martin Rao; Alimuddin Zumla
Journal:  Ann Transl Med       Date:  2015-05

2.  Ex-vivo characterization of regulatory T cells in pulmonary tuberculosis patients, latently infected persons, and healthy endemic controls.

Authors:  Martha Zewdie; Rawleigh Howe; Søren T Hoff; T Mark Doherty; Nahom Getachew; Azeb Tarekegne; Bamlak Tessema; Lawrence Yamuah; Abraham Aseffa; Markos Abebe
Journal:  Tuberculosis (Edinb)       Date:  2016-07-09       Impact factor: 3.131

Review 3.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

4.  The role of T regulatory cell-associated markers in monitoring tuberculosis treatment completion and failure.

Authors:  Sonali Agrawal; Om Parkash; Alangudi Natarajan Palaniappan; Ashok K Bhatia; Santosh Kumar; Devendra S Chauhan; M Madhan Kumar
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

5.  Increased frequency of CD4+ CD25+ FoxP3+ T regulatory cells in pulmonary tuberculosis patients undergoing specific treatment and its relationship with their immune-endocrine profile.

Authors:  Ariana Díaz; Natalia Santucci; Bettina Bongiovanni; Luciano D'Attilio; Claudia Massoni; Susana Lioi; Stella Radcliffe; Griselda Dídoli; Oscar Bottasso; María Luisa Bay
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

Review 6.  Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination.

Authors:  Mardi C Boer; Simone A Joosten; Tom H M Ottenhoff
Journal:  Front Immunol       Date:  2015-05-11       Impact factor: 7.561

7.  Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.

Authors:  Peter Bock; Karen Jennings; Redwaan Vermaak; Helen Cox; Graeme Meintjes; Geoffrey Fatti; James Kruger; Virginia De Azevedo; Leonard Maschilla; Francoise Louis; Colette Gunst; Nelis Grobbelaar; Rory Dunbar; Mohammed Limbada; Sian Floyd; Ashraf Grimwood; Helen Ayles; Richard Hayes; Sarah Fidler; Nulda Beyers
Journal:  J Acquir Immune Defic Syndr       Date:  2018-01-01       Impact factor: 3.731

8.  Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time.

Authors:  Norma A Téllez-Navarrete; Lucero A Ramon-Luing; Marcela Muñoz-Torrico; Mario Preciado-García; Karen Medina-Quero; Rogelio Hernandez-Pando; Leslie Chavez-Galan
Journal:  Mol Med       Date:  2021-07-14       Impact factor: 6.354

9.  Association of Immune Factors with Drug-Resistant Tuberculosis: A Case-Control Study.

Authors:  En-Tao Sun; Dan Xia; Ben-He Li; Jun Ma; Yuan-Yuan Dong; Shu-Shu Ding; Bai-Feng Chen; Yu-Feng Wen
Journal:  Med Sci Monit       Date:  2017-11-09

10.  Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response.

Authors:  Sonali Agrawal; Om Parkash; Alangudi Natarajan Palaniappan; Ashok Kumar Bhatia; Santosh Kumar; Devendra Singh Chauhan; M Madhan Kumar
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.